Gilead Sciences Inc.

21 ago 2026, 20:06 UTC

Gilead Sciences Inc's shares are higher, maintaining upward momentum since Thursday, despite a slight pullback earlier in the session. The stock remains above its 20-day moving average.

20 ago 2026, 23:36 UTC

Gilead Sciences Inc shares are higher in after-market trading. Strong broader market performance and declining initial jobless claims support this positive momentum.

19 ago 2026, 20:02 UTC

Gilead Sciences awarded its U.S. media account to Publicis, shifting from Interpublic. Shares are advancing amid positive investor sentiment and social media discussions.

18 ago 2026, 20:02 UTC

Gilead Sciences shares are higher, trading above $138 amid positive sentiment. Analysts see potential for targets between $140 and $145 with strong support levels.

17 ago 2026, 20:06 UTC

Gilead Sciences shares are advancing, navigating a resistance area and remaining above the 20-day moving average, reflecting continued trader interest.

14 ago 2026, 19:26 UTC

A federal appeals court upheld an injunction against Gilead's HIV medications. Shares reached a four-week high of $138.33, remaining roughly flat since Thursday.

13 ago 2026, 23:11 UTC

Gilead Sciences shares are lower in after-market trading, reflecting routine activity amid broader economic data showing rising jobless claims and steady producer prices.

12 ago 2026, 20:06 UTC

Gilead Sciences announced a collaboration with Nucleai for AI-driven biomarker discovery. Shares are trading lower despite the partnership announcement.

11 ago 2026, 20:06 UTC

Gilead Sciences reported second-quarter revenue of $7.80 billion, exceeding estimates. Shares are higher since Monday, reflecting positive sentiment after the earnings report.

10 ago 2026, 23:06 UTC

Gilead Sciences Inc. shares are higher in after-market hours, reflecting stability with routine trading and no specific news identified.

7 ago 2026, 20:06 UTC

Gilead Sciences reports $65 million in revenue from Kymera Therapeutics collaboration, including a $45 million option exercise fee. Shares are higher despite earlier session pullback.

6 ago 2026, 23:02 UTC

Gilead Sciences filed a mixed securities shelf, raising investor concerns about share dilution. Shares are trading lower in after-market hours.

5 ago 2026, 19:53 UTC

Gilead Sciences shares are lower after reporting a $10.50 billion net loss and revising fiscal 2026 earnings guidance downward, despite strong HIV sales.

4 ago 2026, 23:02 UTC

Gilead Sciences reports a $10.50 billion net loss for Q2, lowering full-year GAAP EPS guidance. Shares are trading lower in after-market hours.

3 ago 2026, 19:51 UTC

Gilead Sciences advances following a California Supreme Court ruling on HIV drug innovation, boosting investor sentiment ahead of Q2 earnings report.

31 jul 2026, 23:16 UTC

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

30 jul 2026, 21:31 UTC

Gilead Sciences shares are lower in after-market hours, continuing a decline since Thursday's close and remaining below the 20-day moving average.

29 jul 2026, 22:41 UTC

Gilead Sciences Inc shares are lower in after-market trading, with no specific news identified to explain the decline amid notable volatility earlier in the session.

28 jul 2026, 23:01 UTC

Gilead Sciences received endorsement for Trodelvy with Keytruda for specific breast cancer patients, boosting shares modestly higher in after-market trading.

27 jul 2026, 18:07 UTC

Morgan Stanley maintains Overweight rating on Gilead Sciences, lowering price target to $165. Shares are higher since Friday, supported by positive news on Trodelvy.

24 jul 2026, 21:41 UTC

Gilead Sciences receives positive CHMP opinion for Trodelvy and Keytruda combination, with shares rising in after-market trading despite broader market volatility.

22 jul 2026, 19:11 UTC

Gilead Sciences Inc is gaining Wednesday, having pulled back earlier in the session. Broader market sentiment is influenced by rising crude oil prices and geopolitical tensions.

21 jul 2026, 19:41 UTC

Gilead Sciences shares are lower after Leerink Partners downgraded the stock to Market Perform and cut the price target to $127 from $146.

20 jul 2026, 23:01 UTC

Gilead Sciences shares are lower in after-market hours following a downgrade from Leerink Partners, citing challenges in the HIV prophylaxis market and revised sales outlook.

17 jul 2026, 19:56 UTC

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

16 jul 2026, 23:41 UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

15 jul 2026, 18:46 UTC

Gilead Sciences Inc shares are higher, reflecting positive momentum in biotechnology amid a declining U.S. Dollar and easing inflation concerns.

14 jul 2026, 23:16 UTC

Gilead Sciences shares are higher in after-market trading, following a steady increase from earlier lows amid softer inflation data and a rally in Treasury bonds.

13 jul 2026, 17:26 UTC

Gilead Sciences is gaining as it prepares for key product launches in 2026, including Bulevirtide and a new HIV regimen under FDA review.

10 jul 2026, 20:01 UTC

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.